GLPwatch
Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program.
Ann Med Surg (Lond) · 2026
Last updated 2026-08-28| Journal | Ann Med Surg (Lond), 2026 |
|---|---|
| Citations | 0 |
| Molecules | orforglipron |
Full record and abstract on PubMed 42433749 ↗
Related research
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.